Cubist Pharmaceuticals achieved positive top-line results from a Phase III trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections (cUTI). Ceftolozane/tazobactam met its primary endpoint of statistical non-inferiority compared to levofloxacin. The primary endpoint was microbiological eradication and clinical cure rate at 5 – 9 days after the end of therapy. The 95% confidence interval around the treatment difference had lower and upper bounds of 2.3...